Key result
Colchicine plus ticagrelor reduces thrombosis more effectively than monotherapy by dampening inflammation and platelet activation.
Why the study?
Thrombus formation is linked to oxidative stress and inflammation, prompting investigation into whether colchicine can treat thrombosis.
Does the combination of colchicine and ticagrelor inhibit carrageenan-induced thrombus formation and attenuate platelet activation, oxidative stress, and inflammation in preclinical mouse and cell models?
Does the combination of colchicine and ticagrelor inhibit carrageenan-induced thrombus formation and attenuate platelet activation, oxidative stress, and inflammation in preclinical mouse and cell models?
Answers are grounded in this paper and cite their sources.
Preclinical evidence demonstrates that combining colchicine with ticagrelor synergistically inhibits thrombus formation by concurrently targeting platelet activation, endothelial oxidative stress, and TLR4-mediated inflammation without hepatotoxicity in mice.
The formation of a thrombus is closely related to oxidative stress and inflammation. Colchicine is one of the most commonly prescribed medication for gout treatment, with anti‐inflammation and antioxidative stress properties. Therefore, we speculated that it is possible for colchicine to treat thrombosis. In this study, we used carrageenan to induce thrombosis in BALB/c mice and fed mice with colchicine, ticagrelor, and their combination, respectively. We found colchicine inhibited carrageenan‐induced thrombi in mouse tail, and the inhibition was enhanced by ticagrelor. In vitro , colchicine inhibited thrombin‐induced retraction of human platelet clots. Mechanically, colchicine inhibited platelet activation by reducing the expression of platelet receptors, protease‐activated receptor 4 (PAR4) and CD36, and inactivating of AKT and ERK1/2 pathways. Furthermore, in human umbilical vein endothelial cells (HUVECs), colchicine showed antioxidative stress effects through increasing protein expression of glutathione peroxidase‐1 (GPx‐1), and mRNA levels of forkhead box O3 (FOXO3a) and superoxide dismutase 2 (SOD2). In RAW264.7 cells, colchicine reduced LPS‐enhanced inflammatory response through attenuating toll‐like receptor 4 (TLR4) activation. In addition, colchicine reduced LPS or ox‐LDL‐induced monocyte adhesion to HUVECs by inhibiting intercellular adhesion molecule‐1 (ICAM‐1) and vascular adhesion molecule‐1 (VCAM‐1) levels. Taken together, our study demonstrates that colchicine exerts antithrombotic function by attenuating platelet activation and inhibiting oxidative stress and inflammation. We also provide a potential new strategy for clinical treatment.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2022) studied Carrageenan-induced thrombosis (n=73). Colchicine and ticagrelor (alone or in combination) vs. PBS vehicle control (with or without carrageenan 50 mg/kg i.p.) and monotherapy arms was evaluated on Carrageenan-induced thrombus formation in mouse tail, liver, and lung vessels (p=<0.05). Colchicine combined with ticagrelor inhibited carrageenan-induced thrombosis in mouse tail, liver, and lung vessels more effectively than either agent alone by attenuating platelet activation, oxidative stress, and inflammation.
Synapse has enriched 10 related papers. Consider them for comparative context: